Our Work

In 2007, Harley Street surgeon Charles Akle established Immodulon Therapeutics with the financial support of a private investor. The ambition from the start was to develop an immunotherapy treatment that would potentially improve the way that cancer is treated in the world today.

Our treatments are natural bacterial products; whole cell, heat killed mycobacteria. They are immune-modulators, meaning they balance towards an appropriate immune response. This might be in some circumstances tuning up the immune response and in others tuning it down.

These modifications can happen at the same time in the same place - but the net result, by restoring the appropriate responses (immune-regulation or immune modulation), can be tumour destruction as for IMM‑101 in cancer, or tempering immune response as for IMM‑201 in Tuberculosis (TB) or Post Traumatic Stress Disorder (PTSD).


IMM‑101 is a naturally derived investigational medicinal product that helps the body’s immune system to recognise and control cancer. It is intended to be used in combination with other anti-cancer treatments to improve the overall outcome for patients. Clinical studies have produced encouraging increases in survival data in patients with pancreatic cancer and advanced melanoma.


IMM‑201 is an environmental bacterium called M. vaccae NCTC11659. It is part of the Immodulon family of immune-modulation treatments. Immune-modulators help the body to restore correct immune functions and, for example control the damage caused by persistent chronic inflammation. IMM‑201 is being used to explore the treatment of non-cancer diseases that cause and are driven by persistent chronic inflammation such as tuberculosis (TB), and mood disorders such as Post Traumatic Stress Disorder (PTSD).